Correction to CureVac 2nd Update Article on Sept. 14
15 Setembro 2021 - 06:08AM
Dow Jones News
In late June, CureVac published final data showing that its
vaccine had demonstrated efficacy of 48% against Covid-19. "CureVac
Shares Fall Premarket on Termination of Vaccine Contracts With
Wacker Chemie, Celonic -- 2nd Update," at 1259 GMT Sept. 14, cited
interim data from mid-June which showed the vaccine demonstrating a
47% efficacy.
(END) Dow Jones Newswires
September 15, 2021 04:53 ET (08:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024